FDA adcomm to review drugs for four different cancers this month

The FDA announced a two-day meeting of its Oncologic Drugs Advisory Committee (ODAC) later this month to review four cancer drugs from Genentech, Pfizer, J&J and UroGen Pharma, with potential new ...